Tag: Opicapone

An estimated 2–3% of the population aged 65 and older suffers from Parkinson's disease (PD), a neurodegenerative disorder affecting movement. For many patients, managing motor fluctuations and 'wearing-off' periods is a key treatment goal, making an understanding of what are the most common COMT inhibitors essential for maximizing the effectiveness of levodopa therapy.

Patients with Parkinson's disease (PD) who have been on long-term levodopa therapy often face motor fluctuations and disabling "off" episodes as the medication's effect wears off. For these individuals, understanding what are the benefits of taking opicapone becomes crucial for optimizing treatment and improving their quality of life. Opicapone is a third-generation catechol-O-methyltransferase (COMT) inhibitor, which plays a key role in extending the availability of levodopa in the brain.

Approximately 2-3% of the population aged 65 or older are affected by Parkinson's disease, a condition often managed using therapies that include a COMT inhibitor. This class of drugs is a crucial tool in the pharmacological management of Parkinson's, specifically for addressing the 'wearing-off' periods that many patients experience.